2014 NCCN Congress Series™: Utilizing Guidelines to Customize Patient Care in NSCLC - Biomarkers and Testing in Lung Cancer
Lung cancer is the leading cause of cancer death in the United States. Oncologists need to be aware of new treatment options and recommendations so they can implement the best treatment plans and thus improve outcomes for their patients with lung cancer. The 2014 NCCN Congress Series™: Utilizing Guidelines to Customize Patient Care in Non-Small Cell Lung Cancer will discuss the most recent developments in diagnosis and treatment to ensure that members of a multidisciplinary team, including physicians, nurses, pharmacists and other relevant healthcare professionals, have the knowledge and skills necessary to apply the standards of care to their practice and healthcare setting for patients with non-small cell lung cancer.
This educational program is designed to meet the educational needs of oncologists, pathologists, nurses, pharmacists, and other healthcare professionals who manage patients with non-small cell lung cancer.
Following this activity, participants should be able to:
- Describe the benefits of molecular testing of tumor tissue as it relates to more appropriate selection of therapy and better outcomes
- Discuss the appropriate use of different types of minimally invasive techniques that may be used to obtain tissue samples for molecular testing
- Analyze current recommendations regarding molecular testing for anaplastic lymphoma kinase (ALK) rearrangements and sensitizing epidermal growth factor receptor (EGFR) mutations
Gregory A. Otterson, MD
The Ohio State University Comprehensive Cancer Center – James Cancer Hospital and Solove Research Institute
This activity is approved for AMA PRA Category 1 Credit(s)™. Nursing and pharmacy (ACPE) credits are also provided. View complete accreditation information
- 1.00 Participation
- 1.00 Nurse
- 1.00 Pharmacist
- 1.00 Physician